Literature DB >> 7905257

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

J Hietala1, E Syvälahti, K Vuorio, K Någren, P Lehikoinen, U Ruotsalainen, V Räkköläinen, V Lehtinen, U Wegelius.   

Abstract

BACKGROUND: According to the D2 dopamine receptor hypothesis of schizophrenia, there is an increased number of D2 receptors in the brains of schizophrenic patients than in those of healthy controls. We tested this hypothesis in 13 newly admitted neuroleptic-naive schizophrenic patients and 10 healthy volunteers using positron emission tomography.
METHOD: The quantification of striatal D2 dopamine receptor density (Bmax) and affinity (Kd) was done using an equilibrium model described for raclopride labeled with carbon 11.
RESULTS: No statistically significant alterations were found in D2 receptor densities or affinities between the patient and control groups. However, a subgroup of four patients with a relatively high striatal D2 dopamine density was identified. Two patients, especially, had D2 dopamine densities almost twice as high as the mean control Bmax value. The Kd values also tended to be higher in this subset of patients than in the controls. No consistent striatal D2 dopamine receptor laterality was observed in schizophrenic patients or controls. However, an association of high D2 dopamine density in the left striatum and the mass of raclopride injected in the scan with low-specific radioactivity was observed in patients but not in controls.
CONCLUSIONS: There are no general changes in D2 dopamine receptor Bmax or Kd values in neuroleptic-naive schizophrenics, but there may be a subgroup of patients with aberrant striatal D2 dopamine receptor characteristics in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905257     DOI: 10.1001/archpsyc.1994.03950020040004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  20 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 2.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

3.  A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Authors:  P Tibbo; P H Silverstone; A J McEwan; J Scott; A Joshua; K Golberg
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

4.  Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.

Authors:  J Tiihonen; M Kuoppamäki; K Någren; J Bergman; E Eronen; E Syvälahti; J Hietala
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

5.  Midbrain dopamine D2/3 receptor binding in schizophrenia.

Authors:  Heli Tuppurainen; Jyrki T Kuikka; Mikko P Laakso; Heimo Viinamäki; Minna Husso; Jari Tiihonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

Review 6.  Dysfunctional brain networks and genetic risk for schizophrenia: specific neurotransmitter systems.

Authors:  Jussi Hirvonen; Jarmo Hietala
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

7.  Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Authors:  Ivonne Suridjan; Pablo Rusjan; Jean Addington; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  J Psychiatry Neurosci       Date:  2013-03       Impact factor: 6.186

8.  Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence.

Authors:  J Hietala; C West; E Syvälahti; K Någren; P Lehikoinen; P Sonninen; U Ruotsalainen
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

9.  Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Authors:  K Blum; M Oscar-Berman; J Giordano; Bw Downs; T Simpatico; D Han; John Femino
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-17

10.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.